F. Hoffmann-La Roche Ltd
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs
1,2,3
administered under the skin in just minutes compared to hours with intravenous (
IV) infusion of Perjeta plus Herceptin
4,5,6
Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered